DARYL T LAU

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients
    Daryl T Y Lau
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Hepatology 47:799-809. 2008
  2. doi request reprint Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection
    Daryl T Y Lau
    Liver Center, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 144:402-413.e12. 2013
  3. pmc Current status of antiviral therapy for hepatitis B
    Daryl T Y Lau
    Associate Professor of Medicine, Harvard Medical School HMS, Director of Translational Liver Research, Beth Israel Deaconess Medical Center, HMS Liver Center, Division of Gastroenterology, Department of Medicine, 110 Francis Street, Suite 4A, Boston, MA 02215
    Therap Adv Gastroenterol 1:61-75. 2008
  4. ncbi request reprint Hepatitis B: the pathway to recovery through treatment
    F Blaine Hollinger
    Department of Medicine, Eugene B Casey Hepatitis Research Center and Diagnostic Laboratory, Baylor College of Medicine, One Baylor Plaza, BCM 385, Houston, TX 77030 3498, USA
    Gastroenterol Clin North Am 35:425-61, x. 2006
  5. ncbi request reprint Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector
    Karla J Helbig
    Infectious Diseases Laboratories and Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia
    Hepatology 42:702-10. 2005
  6. ncbi request reprint Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis
    Daryl T Y Lau
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555 0764, USA
    Hepatology 42:273-81. 2005
  7. pmc Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection
    Yueh Ming Loo
    Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 103:6001-6. 2006
  8. ncbi request reprint The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C
    Ned Snyder
    Department of Internal Medicine, Division of Gastroenterology, The University of Texas Medical Branch, Galveston, Texas 77555 0764, United States
    Clin Chim Acta 381:119-23. 2007

Research Grants

Collaborators

  • Kui Li
  • Michael Gale
  • Jeremie Guedj
  • Wissam Bleibel
  • Jie Chen
  • Takashi Fujita
  • B A Luxon
  • W M Lee
  • Ned Snyder
  • Yueh Ming Loo
  • F Blaine Hollinger
  • Karla J Helbig
  • Shu Yuan Xiao
  • Audrey Nguyen
  • Roger Soloway
  • John Petersen
  • Leka Gajula
  • D Spencer Carney
  • Takeshi Saito
  • Stanley M Lemon
  • Andrea K Erickson
  • Cynthia L Johnson
  • Hisashi Ishida
  • Curt H Hagedorn
  • Ting Wang
  • David M Owen
  • Steven A Weinman
  • Mitsutoshi Yoneyama
  • Penny M Fish
  • Michael R Beard
  • Hugh A J Harley
  • Ljiljana Semendric

Detail Information

Publications8

  1. doi request reprint Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients
    Daryl T Y Lau
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Hepatology 47:799-809. 2008
    ..CONCLUSION: These results indicate that HCV can transiently trigger IRF-3 activation during virus spread and that in chronic HCV, IRF-3 activation within infected hepatocytes occurs but is limited...
  2. doi request reprint Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection
    Daryl T Y Lau
    Liver Center, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 144:402-413.e12. 2013
    ..We used a systems biology approach to evaluate the acute response of patients with chronic hepatitis C to IFN-α therapy...
  3. pmc Current status of antiviral therapy for hepatitis B
    Daryl T Y Lau
    Associate Professor of Medicine, Harvard Medical School HMS, Director of Translational Liver Research, Beth Israel Deaconess Medical Center, HMS Liver Center, Division of Gastroenterology, Department of Medicine, 110 Francis Street, Suite 4A, Boston, MA 02215
    Therap Adv Gastroenterol 1:61-75. 2008
    ..It is equally important to conduct a well designed, prospective natural history study to identify predictors of disease progression. This will accurately guide treatment strategy for this important disease...
  4. ncbi request reprint Hepatitis B: the pathway to recovery through treatment
    F Blaine Hollinger
    Department of Medicine, Eugene B Casey Hepatitis Research Center and Diagnostic Laboratory, Baylor College of Medicine, One Baylor Plaza, BCM 385, Houston, TX 77030 3498, USA
    Gastroenterol Clin North Am 35:425-61, x. 2006
    ..Prevention remains the most effective strategy in the global management of hepatitis B virus. Universal immunization programs prevent hepatitis B virus transmission and circumvent acute and chronic infection...
  5. ncbi request reprint Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector
    Karla J Helbig
    Infectious Diseases Laboratories and Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia
    Hepatology 42:702-10. 2005
    ..Furthermore, ISG viperin has anti-HCV activity in vitro; we postulate that viperin, along with other ISGs, acts to limit HCV replication...
  6. ncbi request reprint Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis
    Daryl T Y Lau
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555 0764, USA
    Hepatology 42:273-81. 2005
    ..Supplementary material for this article can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index/html)...
  7. pmc Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection
    Yueh Ming Loo
    Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 103:6001-6. 2006
    ..HCV protease inhibitors effectively prevent IPS-1 proteolysis, suggesting they may be capable of restoring this innate host response in clinical practice...
  8. ncbi request reprint The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C
    Ned Snyder
    Department of Internal Medicine, Division of Gastroenterology, The University of Texas Medical Branch, Galveston, Texas 77555 0764, United States
    Clin Chim Acta 381:119-23. 2007
    ....

Research Grants5

  1. Racial Differences in IFN Transcriptional Response
    Daryl Lau; Fiscal Year: 2007
    ..between early virological responders and non-responders will lead to a better understanding of host pathways involved in the suppression of hepatitis C virus replication and the induction of a sustained virological response to therapy ..
  2. Racial Differences in IFN Transcriptional Response
    Daryl Lau; Fiscal Year: 2009
    ..between early virological responders and non-responders will lead to a better understanding of host pathways involved in the suppression of hepatitis C virus replication and the induction of a sustained virological response to therapy ..